Pasternak Marcin, Chęciński Maciej, Chęcińska Kamila, Turosz Natalia, Chyży Izabella, Kosiński Bartosz, Kwiatkowska Klaudia, Romańczyk Kalina, Hoppe Amelia, Sikora Maciej
Division of Clinical Pharmacology, Department of Pharmacology, Jagiellonian University Medical College, 16 Grzegórzecka Street, 31-531 Cracow, Poland.
National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137 Str., 02-507 Warsaw, Poland.
Int J Mol Sci. 2025 Sep 10;26(18):8798. doi: 10.3390/ijms26188798.
Intra-articular injections form a substantial element of the temporomandibular joint disorder (TMD) therapy. Given the role played by IL-1β in pathology, the use of autologous conditioned serum (ACS) is well-founded. Despite years of effective use in different locations, data regarding the intra-articular administration of ACS in TMD is scarce, and the strategy itself is not routinely applied. This study aims to provide preliminary evidence on the therapeutic efficacy of administering intra-articular ACS in treating TMD. Patients with TMD who received intra-articular ACS were included. More invasive co-interventions, such as arthroscopy, were excluded. Final searches were conducted on 17 June 2025, using five databases (ACM, BASE, DOAJ, PubMed, and SciELO). Risk of bias was evaluated using the RoB 2 tool. The results were tabulated. Only one study met the inclusion criteria. When compared to dextrose prolotherapy in internal TMD, ACS therapy resulted in greater improvement in mouth opening, pain, and joint-sound reduction. The small sample size, head-to-head design, and limited blinding suggest a highly cautious interpretation of the findings. ACS is a promising, but still experimental, therapeutic strategy addressing critical mechanisms in TMD. However, the currently available data is insufficient to confirm the effectiveness and safety of such an approach, and further high-quality studies are needed. This study received no funding. PROSPERO registration number: CRD420251069310.
关节内注射是颞下颌关节紊乱病（TMD）治疗的重要组成部分。鉴于白细胞介素-1β在病理过程中的作用，使用自体条件血清（ACS）是有充分依据的。尽管ACS在不同地区已有效使用多年，但关于其在TMD关节内给药的数据却很少，而且该策略本身也未被常规应用。本研究旨在为关节内注射ACS治疗TMD的疗效提供初步证据。纳入接受关节内注射ACS的TMD患者。排除了更具侵入性的联合干预措施，如关节镜检查。于2025年6月17日使用五个数据库（ACM、BASE、DOAJ、PubMed和SciELO）进行了最终检索。使用RoB 2工具评估偏倚风险。结果列成表格。只有一项研究符合纳入标准。与TMD内部的葡萄糖增殖疗法相比，ACS疗法在张口、疼痛和关节弹响减轻方面有更大改善。样本量小、直接比较设计以及盲法有限表明对研究结果的解释需高度谨慎。ACS是一种有前景但仍处于实验阶段的治疗策略，可解决TMD的关键机制。然而，目前可得的数据不足以证实这种方法的有效性和安全性，需要进一步开展高质量研究。本研究未获得资金支持。PROSPERO注册号：CRD420251069310。
